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SIGNIFICANCE
The role of Wnt signaling in liver development and tumorigenesis remains elusive. Here we investigated the pathogenesis of
hepatoblastoma, a pediatric tumor strongly associated with mutational activation of b-catenin. By integrating expression
and genetic profiles of clinically annotated tumors, we provide a molecular overview of a previously unrecognized prognos-
tic subtype that evokes cancer stem/progenitor cells. Activation of Myc might play a predominant role in the pathogenesis
of this tumor subtype. We demonstrate that hepatic differentiation stage and clinical behavior of hepatoblastoma are
intimately linked, and we identify an expression signature with dual capacities in recognizing liver developmental stage
and predicting disease outcome. These data can be applied to improve clinical management of pediatric liver cancer
and develop therapeutic strategies.Cancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc. 471
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Hepatoblastoma, the mostcommonpediatric liver cancer, is tightly linked toexcessiveWnt/b-catenin signaling.
Here, we used microarray analysis to identify two tumor subclasses resembling distinct phases of liver devel-
opment and a discriminating 16-gene signature. b-catenin activated different transcriptional programs in the
twotumor types,withdistinctiveexpression ofhepaticstem/progenitormarkers in immature tumors.This highly
proliferating subclass was typified by gains of chromosomes 8q and 2p and upregulated Myc signaling.
Myc-induced hepatoblastoma-like tumors in mice strikingly resembled the human immature subtype, and
Myc downregulation in hepatoblastoma cells impaired tumorigenesis in vivo. Remarkably, the 16-gene signa-
ture discriminated invasive and metastatic hepatoblastomas and predicted prognosis with high accuracy.INTRODUCTION
Fine-tuned control of Wnt/b-catenin signaling is essential for cel-
lular proliferation and proper differentiation during development
and tissue homeostasis, and its forced deregulation leads to
malignant transformation of various cell types. Recently, a major
role has been assigned to the Wnt/b-catenin pathway in mainte-
nance of tissue-specific stem cells and proliferation of epithelial
progenitor cells (Korinek et al., 1998; Lowry et al., 2005). While
the role of Wnt signaling at initial steps of liver organogenesis re-
mains elusive (McLin et al., 2007; Ober et al., 2006), this pathway
stimulates proliferation of the developing liver and governs met-
abolic zonation and essential hepatic functions (Benhamouche
et al., 2006; Micsenyi et al., 2004). Furthermore, aberrant dereg-
ulation of Wnt signaling has been implicated as a major mecha-
nism of liver tumorigenesis (de La Coste et al., 1998).
The cancer stem cell hypothesis surmises that most tumor cell
populations are derived from rare undifferentiated cells with
stem-like capabilities of self-renewal and differentiation (Reya
et al., 2001). Liver cancer stem/progenitor cells have been iso-
lated from human hepatoma cell lines and primary hepatocellular
carcinomas (HCCs) (Ma et al., 2007; Yang et al., 2008), and con-
vincing support has been provided for the notion that some HCC
subtypes are derived from hepatic progenitors (Lee et al., 2006;
Yamashita et al., 2008; Zender et al., 2005). The mechanisms
leading to malignant transformation of stem/progenitor cells
can be effectively addressed in pediatric tumors. Hepatoblas-
toma (HB) is a malignant embryonal tumor of the liver usually di-
agnosed in children younger than 3 years of age (Schnater et al.,
2003; Weinberg and Finegold, 1983). In the absence of underlying
liver disease or viral infection, evidence for genetic/epigenetic
origin of this tumor is provided by increased risk associated
withcongenital anomalies, Beckwith-Wiedemann syndrome, and
familial adenomatous polyposis (FAP), a disorder caused by
germline mutations of the APC gene involved in b-catenin degra-
dation. A further link between HB genetics and the Wnt/b-catenin
pathway is provided by the high rate (50%–90%) of mutations
found in CTNNB1, which encodes b-catenin, placing HB among
the most common human tumors endowed with constitutive ac-
tivation of b-catenin/Tcf signaling (Koch et al., 1999; Taniguchi
et al., 2002; Wei et al., 2000). HB differs from HCC by distinctive
morphological patterns reminiscent of hepatoblasts, the bipotent
precursors of hepatocytes and cholangiocytes, and of their
arrangement in the developing liver (Ishak and Glunz, 1967). His-
tologically, HB is classified into different patterns, including the
frequent fetal pattern that evokes the prenatal fetal liver with472 Cancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Incsheets of uniform, cuboidal cells showing low mitotic activity;
the more immature embryonal type characterized by higher cell
density, enlarged nuclei, and frequent mitosis; macrotrabecular
patterns evoking HCC; and small cell undifferentiated (SCUD)
pattern, suggesting that HB may arise from a primitive, uncom-
mitted progenitor (Zimmermann, 2005). Additionally, admixed
neoplastic mesenchymal derivatives and occasional teratoid
features in mixed-type HBs (20%–40% of cases) suggest multi-
directional differentiation abilities of tumor cells.
Although HB is the predominant type of liver cancer in young
children, this tumor is rare, comprising 1% of total pediatric
malignancies. During the last decades, large international clinical
trials have improved the prognosis of HB patients, resulting cur-
rently in 5-year survival rates averaging 75% (Ortega et al., 2000;
Perilongo et al., 2000; Schnater et al., 2003). Complete surgical
resection or liver transplantation and mainstream treatment
with cytotoxic drugs are essential for achieving favorable long-
term outcome. Despite diverse staging systems worldwide,
common prognostic factors rely on intrahepatic tumor exten-
sion, multifocality, invasion of liver vessels, and distant metasta-
ses (Perilongo et al., 2000), whereas prognostic significance of
histopathologic criteria remains debated. At present, few studies
have addressed whether intrinsic biological differences between
tumors impact HB prognosis. Moreover, new treatments are
urgently needed for advanced-stage tumors, and better under-
standing of HB pathobiology is a prerequisite for developing
targeted therapies.
To gain a comprehensive view of HB pathogenesis, the current
study combined gene expression and array-based comparative
genomic hybridization (aCGH) analysis of clinically annotated
tumors with functional studies in cell lines and murine liver
tumors.
RESULTS
Evidence of Wnt/b-Catenin Activation by Genetic
and Transcriptional Profiling
Gene expression and genetic changes were analyzed in 102 clin-
ically annotated tumor samples from 85 patients (see Tables S1
and S2 available online). We started with a genetic screen of
CTNNB1, AXIN1, and AXIN2, genes that are frequently mutated
in liver cancer. CTNNB1 mutations were detected in 65 cases
(76%). Four cases were from FAP kindreds, indicating germline
mutation of the APC gene; AXIN1 was mutated in 1 of 61 cases
analyzed; and AXIN2 was wild-type. In total, 82% of tumors har-
bored genetic mutations related to the Wnt pathway (Table S1)..
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nontumor liver samples were profiled via Affymetrix HG-U133A
microarrays. Analysis of differentially expressed genes between
tumor and nontumor samples confirmed involvement of Wnt sig-
naling as reported in previous studies (Koch et al., 1999, 2005;
Wei et al., 2000) (Table S3). More specifically, we found upregu-
lation of Wnt signaling components implicated in feedback regu-
lations like AXIN2, the positive effectors LEF1, DVL2, and DVL3,
and the Wnt antagonistsDKK1andDKK4. Moreover, a significant
number of genes upregulated in HB such as GLUL (encoding
glutamine synthetase) and TBX3 are selectively overexpressed
in human and murine HCCs carrying mutant b-catenin (Boyault
et al., 2007; Stahl et al., 2005) (Table 1). We used gene lists
from these two previous studies to perform gene set enrichment
analysis (GSEA), a computational method for assessing enrich-
ment of a predefined gene list in one class as compared with
another (Subramanian et al., 2005). This analysis revealed that
b-catenin-related genes in HCC were significant enriched in HB
versus normal liver (Figure S1; Table S4). Pathway and Gene
Ontology (GO) analysis confirmed deregulation of Wnt signaling
and indicated downregulation of genes involved in liver functions
such as metabolism of amino acids, steroids, fatty acids, glu-
cose, xenobiotics, and alcohol and the complement and coagu-
lation cascade (Tables S5 and S6). Another clear observation was
the strong upregulation of several imprinted genes such as IGF2,
DLK1, PEG3, PEG10, BEX1, MEG3, and NDN, which are abun-
dantly expressed in fetal liver (Figure S2).
Identification of Two HB Subclasses by Gene
Expression Profiling
For robust unsupervised classification, we generated and
screened a series of 24 dendrograms to identify samples that
coclustered irrespective of the method and the gene list used
(see Supplemental Experimental Procedures). We obtained
two robust subgroups of tumors, named robust Cluster 1 (rC1,
n = 8) and robust Cluster 2 (rC2, n = 5) (Figure 1A). Comparison
of rC1 and rC2 expression profiles identified 824 genes (p <
0.001, false discovery rate [FDR] = 0.02) (Table S7). Pathway
and GO analysis pinpointed enrichment in rC2 tumors of cell-
cycle-related genes, particularly spindle checkpoint genes
such as DLG7, CDC2, BUB1, and AURKB (Tables S8 and S9),
which are also activated in human embryonic stem cells and in
aggressive tumors (Assou et al., 2007). Evidence that rC2 tumors
were faster proliferating than rC1 tumors was confirmed by Ki-67
immunostaining (see Figure 2A).
To classify the remaining tumors, we built a sample classifier
based on the expression of 16 of the most differentially expressed
genes between rC1 and rC2 at p < 107 and the 13 robust cluster
samples to train the classifier (Figure 1A; Table S10). Most of
these genes showed drastic variations in expression level during
liver development, such as AFP and the proliferation markers
BUB1 and DLG7. When the signature was employed to classify
the remaining tumors into C1 (rC1-related) and C2 (rC2-related)
subclasses, the same classification was obtained using microar-
ray or quantitative PCR (qPCR) (Figure 1B; Table S11). Because
most patients (19 of 24) received preoperative chemotherapy,
we verified that sample distribution was independent of previous
treatment. Principal component analysis (PCA) clearly showed
that chemotherapy-treated and untreated samples were evenlyCdistributed (Figure S3). Both groups exhibited similar, high rates
of b-catenin mutations, and most tumors showed cytoplasmic
and nuclear staining of the protein. However, b-catenin localiza-
tion was predominantly membranous and cytoplasmic in C1
tumors, whereas it showed frequent loss of membrane anchoring
and intense nuclear accumulation in C2 tumors (Figure 1B). We
observed differential expression of a number of Wnt members
and targets between subclasses. C2 tumors showed increased
expression of MYCN, BIRC5 (encoding survivin), NPM1,
HDAC2, and stem cell-related genes such as TACSTD1 (encod-
ing Ep-CAM), GJA1, and the polycomb gene SUZ12 (Table 1).
Conversely, C1 showed overexpression of genes related to the
liver perivenous area, such as GLUL, RHBG, and two members
of the cytochrome p450 family, CYP2E1 and CYP1A1 (Benha-
mouche et al., 2006; Braeuning et al., 2006) (Table 1; Figure 1C).
GSEA further indicated that the rC1 subclass was enriched in
genes assigned to the hepatic perivenous program (Table S12).
Thus, Wnt/b-catenin signaling appears to activate different
transcriptional programs in HB subtypes.
HB Subclasses Evoke Distinct Phases
of Liver Development
Next, we sought to determine whether HB subclasses were
associated with specific histological phenotypes. Mixed epithe-
lial-mesenchymal tumors in 20% of cases were not significantly
associated with C1 and C2 subclasses. By contrast, a tight asso-
ciation was found with the main epithelial component, which
defines the epithelial cell type occupying more than 50% of tumor
cross-sectional areas. C1 tumors displayed a predominantly
fetal phenotype, including four ‘‘pure fetal’’ cases, whereas C2
tumors showed a more immature pattern, with prevailing embry-
onal or crowded fetal histotypes associated with high prolifera-
tion (p < 0.0001) (Figure 2A). Accordingly, mature hepatocyte
markers were markedly downregulated in C2 compared to C1
tumors (Figure 2B; Table S7), and strong overexpression of the
hepatic progenitor markers AFP, KRT19, and TACSTD1 was
found in C2 HBs (Figures 2A and 2B).
To better define the relationships between HB subclasses and
phases of hepatic differentiation, we first generated a liver devel-
opment-related gene signature using available mouse liver data
sets (Otu et al., 2007) (Table S13). When applied to HB samples,
this signature was able to distinguish by hierarchical clustering
two HB groups closely matching the C1/C2 classification (Fig-
ure S4). Next, we integrated HB gene expression data with the or-
thologous genes expressed in mouse livers at embryonic days
11.5–18.5 (E11.5–E18.5) and at 8 days after birth. In unsupervised
clustering, most C2 tumors coclustered with mouse livers at early
stages of embryonic development (E11.5 and E12.5), whereas C1
tumors gathered with mouse livers at late fetal and postnatal
stages (Figure 2C), supporting the notion that HB subtypes mimic
different points of the hepatic differentiation program.
Gains on Chromosomes 8 and 2 Are Associated
with the C2 Subclass
To explore whether genetic abnormalities might be implicated in
the pathogenesis of the HB subclasses, 24 of the 25 tumors
examined by expression profiling were analyzed by aCGH.
Recurrent chromosomal aberrations consisted of gains on chro-
mosomes 1q (71%), 2q (54%), 6p (25%), 8q (25%), and 20 (21%)ancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc. 473
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Probe Set
Gene
Symbol Gene Name
Fold Change
HB/NL
Fold Change
rC1/rC2 Reference
Ubiquitous Targets
 AXIN2 axin 2 (conductin, axil) upa NS 
204602_at DKK1 dickkopf homolog 1 (X. laevis) 20.2 NS 
221558_s_at LEF1 lymphoid enhancer-binding factor 1 4.8 1.2 
203304_at BAMBI BMP and activin membrane-bound
inhibitor homolog (X. laevis)
3.0 NS Sekiya et al. (2004)
211518_s_at BMP4 bone morphogenetic protein 4 3.0 2.2 
209589_s_at EPHB2 EPH receptor B2 2.0 1.2 
221923_s_at 200063_s_at NPM1 nucleophosmin (nucleolar
phosphoprotein B23, numatrin)
1.8 0.5 
202095_s_at BIRC5 baculoviral IAP repeat-containing 5
(survivin)
NS 0.2 
Stem Cell-Related Targets
201839_s_at TACSTD1 tumor-associated calcium signal
transducer 1
9.7 0.2 Yamashita et al. (2007)
213880_at 210393_at LGR5 leucine-rich repeat-containing G
protein-coupled receptor 5
8.5 NS 
201667_at GJA1 gap junction protein, alpha 1, 43kDa
(connexin 43)
3.8 NS 
219682_s_at TBX3 T-box 3 (ulnar mammary syndrome) 3.5 NS Renard et al. (2007)
212287_at 213971_s_at SUZ12 suppressor of zeste 12 homolog
(Drosophila)
1.7 0.7 Kirmizis et al. (2003)
202936_s_at 218310_at SOX9 SRY (sex determining region Y)-box
9 (campomelic dysplasia,
autosomal sex-reversal)
NS 0.3 
Hepatic Targets
205815_at REG3A regenerating islet-derived 3 alpha
(pancreatitis-associated protein)
15.9 8.6 Cavard et al. (2006)
200648_s_at 217202_s_at
215001_s_at
GLUL glutamate-ammonia ligase
(glutamine synthetase)
4.7 3.4 Cadoret et al. (2002)
202479_s_at 202478_at TRIB2 tribbles homolog 2 (Drosophila) 4.6 NS Boyault et al. (2007)
218704_at RNF43 ring finger protein 43 3.8 NS Boyault et al. (2007)
220510_at RHBG rhesus blood group, B glycoprotein 3.0 NS Boyault et al. (2007)
201833_at HDAC2 histone deacetylase 2 2.0 0.5 Benhamouche et al. (2006)
205244_s_at 205243_at SLC13A3 solute carrier family 13
(sodium-dependent dicarboxylate
transporter), member 3
1.8 NS Boyault et al. (2007)
204310_s_at NPR2 natriuretic peptide receptor
B/guanylate cyclase B
1.8 NS Boyault et al. (2007)
205749_at CYP1A1 cytochrome P450, family 1,
subfamily A, polypeptide 1
0.3 3.1 Braeuning et al. (2006)
1431_at 209975_at 209976_s_at CYP2E1 cytochrome P450, family 2,
subfamily E, polypeptide 1
NS 4.5 Braeuning et al. (2006)
208389_s_at SLC1A2 solute carrier family 1 (glial
high-affinity glutamate
transporter), member 2
NS 1.7 Stahl et al. (2005)
Wnt Pathway-Related Genes
209220_at GPC3 glypican 3 19.5 NS Capurro et al. (2005)
202196_s_at 214247_s_at DKK3 dickkopf homolog 3 (X. laevis) 5.4 8.6 Yue et al. (2008)
201908_at DVL3 dishevelled, dsh homolog 3
(Drosophila)
1.9 NS 
57532_at DVL2 dishevelled, dsh homolog 2
(Drosophila)
1.7 NS 474 Cancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc.
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Probe Set
Gene
Symbol Gene Name
Fold Change
HB/NL
Fold Change
rC1/rC2 Reference
202036_s_at SFRP1 secreted frizzled-related protein 1 0.8 NS 
207468_s_at SFRP5 secreted frizzled-related protein 5 0.7 NS 
206737_at WNT11 wingless-type MMTV integration
site family, member 11
0.7 1.3 
When genes have more than one probe set, mean expression ratios are shown. p < 0.05 was considered significant. NS, no significant change. Unless
otherwise specified, references are available at the Wnt Homepage (http://www.stanford.edu/rnusse/wntwindow.html).
a Assessed by qPCR (fold change = 149.1) in the absence of the AXIN2 probe set on U133A arrays.and losses on 1p (37%) and 4q (33%). Five tumors, of which four
were classified as C1, displayed no large regional change. Inter-
estingly, the frequency of DNA copy gains was elevated by 3-fold
in the C2 subclass, with specific involvement of chromosomes 2
and 8 (Figures 3A and 3B). Three regions of chromosome 2 were
significantly gained in the C2 subclass, including 2q13-q22,
2q36-37, and the entire 2p arm. In particular, four C2 tumors,
but no C1 tumors, gained the 2p arm. The strongest difference
was observed for chromosome 8, with gain of the long arm or
whole chromosome in 6 of 7 C2 tumors, whereas no 8/8q gain
was observed in C1 tumors (p < 0.00005).
The impact of genomic differences on gene expression was
evaluated by GSEA, which showed significant upregulation of
genes localized on chromosomes 2p and 8q in C2 tumors (Fig-
ure 3C; Tables S14 and S15). Next, we checked the expression
of two Myc-family oncogenes, MYCN and MYC, which map to
chromosomes 2p24.1 and 8q24.21. Using microarray data, weCfound increased expression of MYCN in C2 tumors, while MYC
expression was upregulated in C2 versus C1 HBs but was not sig-
nificantly different compared to nontumor livers (Figure 3D). The
impact of Myc expression was investigated by GSEA using a
list of 88 Myc-upregulated target genes validated by chromatin
immunoprecipitation (Zeller et al., 2003). A strong enrichment of
Myc target genes was observed in the C2 subclass, with 66%
of target genes found to be upregulated (Figure 3E; Table S16).
Thus, C2 tumors are characterized by specific chromosomal
gains and activation of Myc signaling.
Effects of Aberrant Activation of b-Catenin or Myc
on Differentiation and Tumorigenicity of Murine
Hepatoblasts In Vitro
To gain more insight into the oncogenic role of b-catenin and
Myc-family genes in hepatic progenitor cells, we used murine
hepatoblast BMEL cell lines that present features of bipotentialFigure 1. Identification of Two Hepatoblas-
toma Subclasses by Expression Profiling
(A) Schematic overview of the approach used to
identify robust clusters of samples, including two
tumor clusters (rC1 and rC2) and one nontumor
cluster (NL), and to classify hepatoblastoma (HB)
samples using six different algorithms (CCP,
LDA, 1NN, 3NN, NC, and SVM) and leave-one-
out cross-validation.
(B) Top: molecular classification of 25 HB samples
and CTNNB1 gene status. Black and gray squares
indicate mutations of the CTNNB1 and AXIN1
genes. Bottom: immunohistochemical analysis of
b-catenin for representative C1 and C2 cases.
Scale bars = 50 mm.
(C) Expression of representative Wnt-related and
b-catenin target genes (p < 0.005) in HB sub-
classes and nontumor livers (NT). Horizontal bars
indicate mean values.ancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc. 475
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Genomics of HepatoblastomaFigure 2. HB Molecular Subclasses Are Related to Liver Development Stages
(A) Distinctive histologic and immunostaining patterns of HB subclasses C1 and C2. From top to bottom: numbers indicate the ratios of mixed epithelial-
mesenchymal tumors and tumors with predominantly fetal histotype in C1 and C2 subtypes; hematoxylin and eosin (H&E) and immunostaining of Ki-67, AFP,
and GLUL in representative samples. Scale bars = 50 mm.
(B) Expression of selected markers of mature hepatocytes and hepatoblast/liver progenitors in HB subclasses and human nontumor livers (NL). Red brackets
indicate statistical comparison of expression levels in C1 and C2 subtypes (*p < 0.05, **p < 0.005, ***p < 0.0005).
(C) Representative unsupervised hierarchical clustering of integrated gene expression profiles from human tumors and mouse livers at different developmental
stages. PN8, mouse liver at 8 days after birth; FL, fetal mouse liver (E11.5–E18.5); HB, hepatoblastoma.embryonic liver stem cells (Strick-Marchand and Weiss, 2002).
BMEL-9A1 cell lines stably expressing either active mutant
b-catenin or N-myc were generated, and c-Myc was transduced
into BMEL lines 9A1 and 14B3 by adenoviral vector (Figure S5A).
Analysis of the 16-gene expression profile by qPCR followed by
classification using the six algorithms assigned a C1-like expres-
sion profile to control BMEL cells (Figure S5B; Table S17). By
contrast, marked expression changes leading to classification
as C2-type were seen in cells overexpressing b-catenin or Myc
genes, with marked downregulation of the hepatocyte markers
Aldh2, Apcs, and Apoc4 in b-catenin-transduced cells and
pronounced upregulation of proliferation-related genes such as
Bub1 and Dlg7 in Myc-overexpressing cells (Figure 4A).
Functional correlates of these changes were explored by
comparing the capacity of these BMEL lines to respond to differ-
entiation and growth signals. BMEL cells can be induced to
express markers of normal hepatocyte function when cultured
as aggregates (Strick-Marchand and Weiss, 2002). The different
stable cell lines were induced to form aggregates by 5-day incu-
bation in nonadherent conditions, and expression of hepatocyte-
specific markers was compared between basal cultures and
aggregates by qPCR. In control BMEL cells, expression of these
genes was strongly activated in aggregates compared with basal476 Cancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Incconditions, while overexpression of b-catenin or N-myc drasti-
cally impaired induction (Figure 4B). We next tested whether
overexpression of b-catenin or N-myc might confer anchorage-
independent growth properties to these cells. In soft-agar exper-
iments, the BMEL-b-cat cell line developed only a few small
colonies, while BMEL cells expressing N-myc formed numerous
colonies after 4 weeks of plating. Overexpression of both genes
did not confer any additional growth advantage to the cells
(Figure 4C). These results implicate both b-catenin and Myc in
regulating differentiation of murine hepatoblasts, while N-myc
displays transforming potential in vitro.
Myc-Induced Liver Tumors Display C2-like
HB Phenotype
We sought to address the involvement of Myc signaling in the
pathogenesis of human HBs by using a conditional MYC trans-
genic mouse model that develops HB-like tumors (Shachaf
et al., 2004; Goga et al., 2007). Histologic analysis of liver tumors
from TRE-MYC 3 LAP-tTA mice showed a hepatoblast-like
atypical morphology that is observed in undifferentiated HB
(Figure 4D). By qPCR analysis, HB marker genes such as Dlk1,
Tacstd1, and the imprinted genes Bex1, Igf2, Meg3, Peg3, and
Peg10 were strongly overexpressed in mouse Myc-induced.
Cancer Cell
Genomics of HepatoblastomaFigure 3. Specific Genetic Profiles of HB Subclasses
(A) Box-plot representation of DNA copy changes in the two HB subclasses. Boxes represent 25–75 percentile range; vertical lines represent 10–90 percentile
range; horizontal bars represent median. *p < 0.01.
(B) Chromosome-by-chromosome representation of genomic profiles in HB subclasses C2 (top) and C1 (bottom). For each chromosome, DNA clones were
stretched on the x axis along with their position. Genomic alteration frequency is indicated on the y axis (log2 scale), where positive values correspond to gains
and negative values to losses. Significant differences between C1 and C2 were evaluated by Fisher’s exact test: red, p < 0.001; orange, p < 0.005; yellow, p < 0.01;
gray, no statistical significance.
(C) Gene set enrichment analysis (GSEA) plots using gene sets mapping to chromosomes 2p (gene set S = 227 genes, false discovery rate [FDR] = 0.183) and 8q
(gene set S = 169 genes, FDR = 0.051).
(D) Box-plot analysis of MYCN and MYC expression in C1 and C2 subclasses and in nontumor livers (NT), as in (A). AU, arbitrary units. *p < 0.05.
(E) GSEA plot showing enrichment of upregulated Myc target genes in C2 versus C1 HBs (gene set S = 88 genes, FDR < 0.001) (Zeller et al., 2003).tumors (Figure S5C). Moreover, similar to human C2 HBs, murine
tumors exhibited strong expression of Afp by immunohisto-
chemical analysis, and despite consistent cytoplasmic localiza-
tion of b-catenin, which indicates Wnt pathway activation, they
did not express Glul (Figure 4D). Finally, four Myc-induced
tumors were profiled by qPCR with the 16-gene signature. In
unsupervised analysis, these tumors coclustered with human
rC2 HBs (Figure 4E), and using a class discovery approach, all
six algorithms readily classified the murine tumors in the C2
subclass. These data support a primary role of Myc in the
pathogenesis of immature human HBs.
Sustained Myc Expression Is Required for Maintaining
C2-like Phenotype and Tumorigenic Potential
of Established HB Cell Lines
We next evaluated the impact of b-catenin and Myc activation on
HB phenotype using RNA interference in Huh6 and HepG2 cellClines derived from pediatric HB or HB/HCC. These cells carry
mutantb-catenin alleles and abundantly express c-Myc, showing
approximately 30-fold higher expression levels for MYC than
for MYCN by qPCR analysis (data not shown). Given the high
functional redundancy of Myc proteins (Malynn et al., 2000), we
focused on the effects of c-Myc inhibition. Transfection of Huh6
and HepG2 cells with b-catenin or c-Myc siRNAs resulted in
significant decrease of the target proteins compared to cells
transfected with nontargeting scrambled control (SC) siRNA
(Figure 5A). The b-catenin siRNA more efficiently suppressed
wild-type and mutated (G34V) b-catenin in Huh6 cells than the
N-terminally deleted protein in HepG2 cells, but strong repres-
sion of the Wnt target c-Myc was observed in both cell lines
(Figure 5A).
Analysis of the 16-gene signature in Huh6 and HepG2 cells in-
dicated that cells transfected with control siRNA classified as C2
HBs, consistent with high levels of Myc expression (Figure 5B).ancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc. 477
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(A) Expression of the 16 genes of the HB classifier in BMEL cells overexpressing b-catenin or Myc genes. Values are expressed as fold change compared with
control BMEL cells. Red and green bars indicate high and low expression, respectively. Black bars indicate <0.6-fold log change (1.5-fold in linear scale).
(B) Expression of differentiation markers in BMEL cells stably overexpressing b-catenin or N-myc. BMEL cells transduced with empty pBabe vector were used as
control. Data are given as normalized fold-change expression.
(C) Colony formation in soft agar. Error bars = SD; scale bar = 1 mm.
(D) Histology and immunohistochemistry of murine Myc-induced tumors (T) and normal livers (NT). pv, perivenous area. Scale bars = 50 mm.
(E) Unsupervised hierarchical clustering analysis of four murine Myc-induced tumors (MYC1–4) and human rC1 and rC2 HB samples using the 16-gene signature.Cells transfected with b-catenin or c-Myc siRNA showed a dra-
matic change in gene expression leading to a C1-like profile. As
C2 HBs differ from C1 HBs by high proliferative activity, we mea-
sured proliferation of cells transfected with b-catenin, c-Myc, or
SC siRNAs. Comparison of proliferation curves showed that
proliferation of HepG2 and Huh6 cells was impaired by b-catenin
or c-Myc siRNA (Figure 5C). We next compared the effects of
b-catenin and Myc on cell tumorigenicity. We have shown re-
cently that inhibition of b-catenin impairs anchorage-indepen-
dent growth of hepatoma cells in vitro (Renard et al., 2007). We
tested the ability of Huh6 and HepG2 cells to form colonies in
soft agar after treatment with siRNAs for b-catenin or c-Myc.
Consistent with proliferation data, colony formation was reduced
by 5- to 8-fold in sib-catenin- and siMyc-transfected cells at
3 weeks after plating compared to cells transfected with SC
siRNA (Figure 5D). To extend our studies to an in vivo setting,
Huh6 cells at 48 hr after transfection with siRNA for b-catenin,
c-Myc, or SC siRNA were injected subcutaneously into nude
mice (n = 4 for each experimental condition). Control siSC-
transfected cells formed tumors in mice in less than 3 weeks,
while tumors developed after 4 weeks in mice injected with478 Cancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Incsib-catenin-transfected cells and after 5 weeks in mice injected
with cells transfected with siMyc-transfected cells (Figure 5E).
Thus, Myc appears to play a crucial role in the tumorigenicity of
HB-derived cells.
The 16-Gene Signature Is a Strong Independent
Prognostic Factor
To investigate the clinical relevance of HB molecular classifica-
tion, the 16-gene HB classifier was assessed in a new set of
77 HB samples from 61 patients by qPCR (Figure 6A; Tables S1,
S2, and S11). Extending our previous observation, C1/C2 classi-
fication of this new tumor set using the six algorithms was unre-
lated to CTNNB1 mutation rate. Using qPCR, we also confirmed
enhanced expression of the liver progenitor markers AFP,
TACSTD1, and KRT19 in C2 tumors (Figure S6). Moreover, while
a similar percentage of C1 and C2 tumors displayed mesenchy-
mal components, 95% of C1 tumors showed a predominantly
fetal histotype, whereas in 82% of C2 tumors, the major compo-
nent displayed less differentiated patterns such as embryonal,
crowded fetal, and macrotrabecular (p < 0.0001) (Table S1). To
further assess the association of HB subclasses with liver.
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Phenotype and Tumorigenicity of HB Cell
Lines In Vivo
(A) Immunoblot analysis of b-catenin (upper panel)
and c-Myc (lower panel) in HepG2 and Huh6 cells
transfected with b-catenin (b-Cat), c-Myc, or
scrambled (SC) siRNA. Unless indicated, cell
extracts were prepared 96 hr posttransfection.
DN b-Cat indicates mutated form of b-catenin in
HepG2 cells.
(B) Classification of HepG2 and Huh6 cells treated
with siRNAs against b-catenin (sib-Cat), c-Myc
(sic-Myc), or nontargeting control (siSC) shown in
representative clustering with rC1 and rC2 HB
samples.
(C) Cell proliferation in HepG2 and Huh6 cell lines
transfected with sib-Cat, sic-Myc, or siSC. Error
bars = SD.
(D) Soft-agar assay. HepG2 and Huh6 cells were
transfected with siRNAs specifically targeting
b-catenin, c-Myc, or nontargeting control (SC) as
indicated. Colony number is expressed as per-
centage of colonies in siSC-transfected cells.
Error bars = SD.
(E) In vivo tumorigenesis assays. Data are
presented as mean tumor volume ± SD.development, five human fetal livers at different weeks of gesta-
tion were included in the qPCR studies. Fetal livers at late (>35
weeks) and earlier (17–26 weeks) developmental stages were
classified as C1 and C2, respectively, further supporting that HB
subclasses reflect different developmental phases (Figure 6A).
The clinical impact of HB molecular classification was
addressed in the complete set of patients, comprising 54 C1
(63%) and 31 C2 (36%) cases. Besides strong association with
predominantly immature histotypes, C2 HBs were tightly associ-
ated with features of advanced tumor stage, such as vascular
invasion and extrahepatic metastasis (Figure 6B). Accordingly,
overall survival of these patients was markedly impaired. Ka-
plan-Meier estimates of overall survival probability at 2 years
were 44% for patients with C2 tumors and 92% for patients
with C1 tumors (p < 0.0001), and similar trends were seen for
disease-free survival (data not shown). The observation of higher
numbers of C2-type cases in diagnostic biopsies compared to
posttreatment specimens prompted us to examine whether
preoperative chemotherapy treatment could affect tumor classi-
fication. We compared the 16-gene expression profiles between
untreated and treated samples by t test and found no significant
difference. We then examined the performance of the 16-gene
signature in untreated and treated samples. Analysis of the
73 samples resected after chemotherapy showed a significant
difference in outcome between patients with C1 and C2 HBs
(p = 0.0001) (Figure 6C). Remarkably, Kaplan-Meier analysis also
confirmed the C2 subclass as a poor prognostic group in 28
cases for which biopsies or surgery specimens before chemo-
therapy were available (p = 0.0283) (Figure 6C). Thus, increased
frequency of C2 subtypes in untreated versus posttreatment
samples is likely related to clinical practice, as diagnostic biop-
sies are prescribed mostly for clinically unfavorable cases. Col-
lectively, these data strongly suggest that chemotherapy does
not significantly modify the expression profiles used for molecu-
lar classification of HB. Of note, available pretreatment biopsiesCwere assigned to the same subclass as matched resected
tumors in 14 out of 16 cases (see Figure 6A; Table S2).
We further assessed the prognostic validity of the 16-gene
signature for all patients in multivariate analysis, using a Cox pro-
portional hazards model with pathological and clinical variables
associated with patients’ survival. This analysis identified the
signature as an independent prognostic factor, with better
performance than tumor stage defined by pretreatment extent
of disease (PRETEXT), vascular invasion, and extrahepatic me-
tastases (Figure 6B). Thus, this signature demonstrates strong
prognostic relevance when compared to current clinical criteria.
DISCUSSION
In this paper, integrated molecular and genetic studies of hepa-
toblastoma disclosed two major molecular subclasses of tumors
that evoke early and late phases of prenatal liver development.
Major differences in expression profiles of the two HB subtypes
led us to elucidate a 16-gene signature that proved highly effi-
cient in stratifying HBs as well as normal livers according to
hepatic developmental stage. Using this signature, we could
establish a tight correlation between stage of hepatic differenti-
ation and clinical behavior, notably vascular invasion, metastatic
spread, and patient survival (Figure 7). Aberrant activation of the
Wnt pathway represents a seminal event in both tumor types,
with cumulated mutation rates of b-catenin, APC, and AXIN
over 80%. Additionally, the interplay of Wnt/b-catenin and Myc
signaling in immature tumors activates a distinct transcriptional
program that correlates with tumor aggressiveness.
HB Molecular Subclasses Are Determined by Liver
Differentiation Stages
Here we present a robust methodological approach for molecular
classification that relies entirely on tumor transcriptional profiling,
independently of sample-associated genetic, histologic, andancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc. 479
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(A) Expression profiles of the 16 genes forming the HB classifier are shown as a heat map indicating high (red) and low (green) expression according to a
log2-transformed scale. HBs and human fetal livers (FL) at different weeks (w) of gestation were assigned to class 1 or 2 using the 16-gene expression profile.
Black boxes in the rows above the heat map indicate (from top to bottom) human fetal liver, mixed epithelial-mesenchymal histology, predominantly fetal
histotype, and b-catenin mutation. Gray boxes indicate familial adenomatous polyposis (FAP) cases.
(B) Top: association of clinical and pathological data with HB classification (chi-square test). Pretreatment extent of disease (PRETEXT) IV stage indicates tumor
involvement of all liver sections. Bottom: multivariate analysis including three variables associated with patient survival. The predominant histotype is defined as
either fetal or nonfetal (including embryonal, crowded fetal, or macrotrabecular types). Tumor stage is defined by vascular invasion, distant metastasis at
diagnosis, and PRETEXT stage. HR, hazard ratio; CI, confidence interval.
(C) Top: Kaplan-Meier plots of overall survival for 73 patients that received preoperative chemotherapy. Bottom: overall survival of 28 HB patients for which
pretreatment biopsies or primary surgery specimens from untreated patients were available.clinical annotations. In the absence of predefined class labels,
this approach does not fulfill classical criteria of predictive analy-
sis, and validation of the classifier efficacy was provided by
strong association of each subclass with identical clinical and
pathological parameters in two different tumor sets.
The most significant difference between HB subclasses can
be ascribed to distinct hepatic differentiation stages, as defined
by comparison with mouse livers at various embryonic stages
and by morphological patterns. The C1 subclass recapitulates
liver features at late stages of intrauterine life, with an expression
profile similar to murine livers at E14.5–E18.5 and a mostly fetal
histotype, while the C2 subclass resemble earlier stages of liver
development, with a transcriptional program evoking murine480 Cancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc.livers at E11.5–E12.5 and a predominantly embryonal histotype.
These results are in line with recent studies using cross-species
comparisons. Clinically distinct medulloblastoma subtypes have
been identified by their similarity with precise stages of murine
cerebellar development (Kho et al., 2004). Similarly, Wilms’ tu-
mor shares expression of stemness and imprinted genes with
murine metanephric blastema (Dekel et al., 2006). A salient fea-
ture of immature HBs is the characteristic interplay of stemness
and high proliferation found in aggressive tumors (Glinsky et al.,
2005). The C2 expression profile is significantly enriched in
markers of hepatic progenitor cells such as cytokeratin 19 and
Ep-CAM (Roskams, 2006), as well as in mitotic cell-cycle and
spindle assembly checkpoint regulators, including cyclin B1,
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Genomics of HepatoblastomaBUB1, BUB1B, and Aurora kinases. Overexpression of these
kinases or other components of the spindle checkpoint induces
centrosome amplification and defects in chromosome segrega-
tion leading to chromosome number instability and aneuploidy
(Marumoto et al., 2005).
Context-Dependent Transcriptional Programs
Driven by Wnt Signaling
Mutational activation of b-catenin is a hallmark of HB, and ac-
cordingly, intracellular accumulation of the protein was observed
in virtually all tumors, albeit with variable frequencies and intensi-
ties. Both immature and differentiated tumors overexpressed
AXIN2 and DKK1, in an attempt to activate a negative feedback
loop aimed at limiting the Wnt signal. However, the two HB
subtypes showed significant differences in b-catenin immunoex-
pression, with nuclear accumulation and decreased membra-
nous localization of the protein in poorly differentiated tumors.
Heterogeneous distribution of nuclear b-catenin within colorectal
tumors has been linked to different levels of Wnt signaling activity
Figure 7. Summary of Biological and Clinical Characteristics of HB
Subclasses
Steps of normal liver development are shown at the top. HB might arise from
impairment of the normal liver differentiation program associated with exces-
sive Wnt/b-catenin signaling. Activation of Myc signaling that characterizes the
aggressive tumor phenotype might depend on genetic alterations or tumor
differentiation stage. The table below lists major distinctive features of the
two HB subtypes.Cresulting from differential combinations of autocrine and para-
crine factors (Fodde and Brabletz, 2007). In immature HBs,
nuclear b-catenin might be related to the absence of membra-
nous E-cadherin, as we have reported previously (Wei et al.,
2000), and/or to cross-talk with growth-stimulating pathways
evidenced in less differentiated cells (Wu et al., 2008).
The differential expression of hepatic Wnt targets in HB sub-
types raises the possibility of context-dependent activation of
Wnt target genes. In the liver, Wnt/b-catenin signaling is known
to govern metabolic zonation by positively controlling the perive-
nous gene expression program and negatively controlling the
periportal program (Benhamouche et al., 2006). In C1 HBs,
hepatic perivenous markers such as GLUL were overexpressed
and genes encoding periportal functions such as GLS2 were
downregulated, while the zonation-related profile was lessened
in C2 HBs. This might reflect the cooperation of b-catenin/Tcf
with liver-enriched factors that are downregulated in immature
tumors. Moreover, cell-type-specific regulation of Wnt targets
might comprise multilayered control systems involving distinct
promoter occupancy by TCFs and epigenetic factors (Merrill
et al., 2001; Wohrle et al., 2007).
Genetic Instability in Poorly Differentiated Tumors
The profile of genetic aberrations determined here by aCGH
revealed a limited number of chromosomal imbalances in HB,
in general agreement with previous karyotyping and CGH studies
(Tomlinson et al., 2005; Weber et al., 2000). Gains on chromo-
somes 8q and 20 in HB have been associated with poor outcome
(Weber et al., 2000). However, relationships between genetic
defects and HB histotypes have not been addressed so far. By
integrating genetic data with expression profiling, we have pro-
vided evidence for a strong association of immature and aggres-
sive HBs with chromosomal instability. This trait was manifested
by increased DNA copy gains, particularly on chromosomes
2 and 8, and to a minor extent on chromosome 20. These alter-
ations likely influence tumor phenotype, as E2F5 (chromosome
8q21) and BUB1 (chromosome 2q14) belong to the 16-gene HB
classifier. Among candidate genes on chromosomes 2p and 8q
that could play a role in the aggressive HB phenotype, MYCN
and MYC are frequently overexpressed in human cancer and
are associated with poor prognosis (Vita and Henriksson, 2006).
Influence of Myc Activation on Proliferation,
Differentiation, and Tumorigenesis in Hepatic
Model Systems
Our studies provided evidence for a drastic role of Myc deregu-
lation in different experimental systems. When overexpressed in
murine hepatoblasts, N-myc induced a shift from C1-like type
to C2-like type. However, N-myc alone or in association with
b-catenin failed to confer tumorigenic properties to BMEL cells
in immunocompromised mice (unpublished data). This might
be related to the wild-type p53 background in these cells, as
suggested by previous work (Zender et al., 2005). Conversely,
inhibition of b-catenin or c-Myc in established hepatoblastoma
cell lines converted the C2-like phenotype to a milder, C1-like
profile. Impaired tumorigenesis conferred by Myc repression in
cells with constitutively activated b-catenin argues for a role of
Myc genes as main effectors of the oncogenic Wnt/b-catenin
pathway in aggressive HBs.ancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc. 481
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HCC development in mice (Vita and Henriksson, 2006). Our find-
ing that mouse liver tumors induced by c-Myc resemble imma-
ture human HBs suggests that the 16-gene signature enables
the identification of Myc activation in liver tumors and might
represent a valuable tool to stratify patients amenable for direct
or indirect therapeutic targeting of Myc (Goga et al., 2007; Vita
and Henriksson, 2006).
Clinical Implications
The correlation between clinical behavior and differentiation/pro-
liferation status observed in HB is common to many human solid
tumors. In our study, this correlation was mainly determined by
differences in tumor invasive properties, clinical tumor stage,
and patient outcome. Most importantly, we have shown that
the 16-gene HB classifier discriminates aggressive tumors, ex-
hibits powerful survival predictor capacities, and demonstrates
strong prognostic relevance when compared to clinical criteria
in multivariate analysis. In current clinical practice, frequent cellu-
lar heterogeneity in HBs has hampered the use of histopathologic
criteria as a prognostic tool. The expression signature afforded
here enables direct appraisal of the global degree of tumor cell
maturation, allowing the bypass of these difficulties. Moreover,
the signature shows equal prognostic capacity when applied
to diagnostic biopsies or posttreatment resected tumors, and
when assayed on paired samples, it assigns almost 90% of biop-
sies and matched treated samples to the same category. Further
studies in larger series are needed to warrant the use of a clinical
tool based on the molecular signature to improve the outcome
prediction and clinical management of HB.
In light of recent evidence showing that HCC subtypes with
poor prognosis may arise from hepatic progenitor cells (Lee
et al., 2006; Roskams, 2006; Yamashita et al., 2008), it would
be worth examining the value of the genomic signature described
herein for classification of common adult liver tumors. Moreover,
the present study offers an opportunity to identify therapies
matching the mechanisms that lead to malignant transformation
of liver progenitor cells.
EXPERIMENTAL PROCEDURES
Patients and Tissue Samples
A total of 102 tumor specimens and biopsies from 85 patients with HB were
collected from different hospitals in France (77 cases), Italy (6 cases), the UK
(1 case), and Switzerland (1 case). Seventy-three patients received chemother-
apy treatment prior to surgery, most being enrolled in clinical trials of the Inter-
national Childhood Liver Tumour Strategy Group (SIOPEL) (Perilongo et al.,
2000). Tumor and liver samples were snap frozen and stored at 80C.
Tables S1 and S2 describe patient characteristics and clinicopathological pa-
rameters. Histology of all tumor specimens was centrally reviewed by an expert
pathologist (M.F.). The study was approved by the Biomedical Research Com-
mittee of Institut Pasteur, and informed consent was obtained at each medical
center in accordance with European Union guidelines for biomedical research.
Gene Mutation Analysis
CTNNB1 mutational screening was performed as described previously (Wei
et al., 2000). Primer sequences and PCR protocol for AXIN1 and AXIN2 muta-
tion screening are described in Supplemental Experimental Procedures.
Oligonucleotide Microarrays
25 HB samples and 4 nontumor samples were selected for Affymetrix
HG-U133A oligonucleotide array analysis based on RNA quality (28S/18S ratio482 Cancer Cell 14, 471–484, December 9, 2008 ª2008 Elsevier Inc> 1.5, RIN [RNA integrity number] > 8; Agilent 2100 Bioanalyzer), complete clin-
ical annotations, expert pathological review, and representative coverage of
clinicopathological situations. Total RNA was prepared using the FastPrep
system (Qbiogene) and an RNeasy Mini Kit (QIAGEN). E18.5 mouse fetal livers
and postnatal livers at 8 days after birth were profiled on Affymetrix MG-U74A
and B v2 arrays according to the manufacturer’s instructions. Data analysis is
described in detail in Supplemental Experimental Procedures.
Array-Based Comparative Genomic Hybridization
Genomic DNA from 24 HBs and 3 nontumor samples was analyzed on chips
containing 3400 sequence-verified PAC/BAC clones spaced at approximately
1 Mb intervals. Array CGH protocol and data analysis are described in Supple-
mental Experimental Procedures.
Quantitative PCR Analysis
Total RNA was extracted from human and murine liver tissues and cell lines
(28S/18S ratio > 1.0, RIN > 7), and human fetal liver RNAs were purchased
from BioChain Institute, Inc. cDNA was generated by using SuperScript II
reverse transcriptase (Invitrogen) with random primers (Promega) according
to the manufacturer’s protocol. For qPCR, we used Sybr Green Master Mix
(Applied Biosystems) and an ABI PRISM 7900HT instrument. Reference genes
were chosen as described in Supplemental Experimental Procedures.
Cell Culture, Transfection, and Soft-Agar Assays
Cell lines, transfection protocols, and proliferation and soft-agar assays are
described in Supplemental Experimental Procedures.
Myc-Driven Liver Tumor Model
Myc-driven liver tumors were generated as described previously (Goga et al.,
2007). Briefly, TRE-MYC mice were crossed to LAP-tTA (liver-specific pro-
moter) mice. Animals were maintained on doxycycline (200 mg/kg doxy
chow) to suppress MYC expression until 8 weeks of age. Doxycycline was
then removed, and mice were followed for evidence of tumor formation. All
experiments were approved by the Committee on Animal Research at UCSF.
Human Xenografts
Female athymic nu/nuBalb/c mice (8 weeks of age, Charles River Laboratories)
were inoculated subcutaneously with 5 3 106 Huh6 cells in 1 ml PBS. Tumor
volume (v) was determined in mm3 by measuring the tumor length (l) and width
(w) and calculated using the formula: v = lw2/2. Tumors were fixed and sec-
tioned for histologic analysis. All procedures were performed according
to protocols approved by the Animal Facility veterinarian board of Institut
Pasteur.
Western Blotting and Immunohistochemistry
Protocols and antibodies are described in Supplemental Experimental Proce-
dures.
Clinical Data Analysis
We used the chi-square test for comparisons between groups. Survival curves
were calculated using the Kaplan-Meier method and the log-rank test. Vari-
ables independently related to survival were determined by stepwise forward
Cox regression analysis.
ACCESSION NUMBERS
Microarray data described herein are available at ArrayExpress (http://www.
ebi.ac.uk/microarray-as/ae/) under the accession numbers E-MEXP-1851
(HB transcriptome), E-MEXP-1852 (HB aCGH), and E-MEXP-1853 (mouse
liver).
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